There is a major mistake in the order of Figure 5 to Figure 7 in \[[@B1]\]. We replce the Figure 5 and Figure 6 in \[[@B1]\] with new corrected Figures of Figure [1](#F1){ref-type="fig"} and Figure [2](#F2){ref-type="fig"}. We also replace the correct original order of Figure 6 and Figure 7 in \[[@B1]\] with Figure [2](#F2){ref-type="fig"} and Figure [3](#F3){ref-type="fig"} in this correction. Sorry for the inconveniences!

![**Combination of 0.05% Triton and 0.2 mg/ml heparin give the optimal refolding activities to cleave the synthetic coumarin-labelled peptide substrate, Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2.***Panel***A**: Shows the refolded ZBD activities increased in dose-dependent manner. In the absence of the refolding accessory factors, Triton X-100 and heparin. The significant reduced activities in the high-concentration (\> 100 μg/ml) was observed which could be due to autolysis. *Panel***B**: Under 37°C incubation for 18 hours, Triton X-100 and heparin can prevent the activity loss. (All experiments were repeated at two batch of purification and refolding preparation and data collected from a representative experiments)](1423-0127-19-87-1){#F1}

![**The polymerization of the 6 kDa ZBD of MMP-7 in pentomer and Octmer demonstrate the significant proteolytic activities towards to the CM-transferrin substrate in CM-transferrin zymographic assay.** 300 μg of craboxylmethylated transferrin (CM-transferrin) was co-polymerized with SDS-PAGE as a substrate gel for analyzing the MMP-7 activities in situ](1423-0127-19-87-2){#F2}

![**Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 assay for characterization of refolded ZBD.***Panel***A**: Under the optimized conditions, the refolded ZBD shows increasing enzymatic activity in dose-dependent manner. No significant activity loss was found in the high concentration situation. *Panel***B**: approximately 6 ng/ml refolded ZBD shows the increasing activity during the time course study and no significant activity loss during overnight incubation. *Panel***C**: Recombinant ZBD can be inhibited by 10 nM EDTA, 1 mM CoCl2 and synthetic inhibitors, 50 nM BB94 & SC44463 and CoCl2, but not b6 250 nM Phosphoramidon. (All experiments were repeated at two batch of purification and refolding preparation and data collected from a representative experiments)](1423-0127-19-87-3){#F3}
